Cullinan Therapeutics, Inc.
CGEM
$8.75
$0.1051.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.54M | 14.56M | 13.35M | 13.77M | 12.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.00M | 55.05M | 48.86M | 50.03M | 42.99M |
| Operating Income | -55.00M | -55.05M | -48.86M | -50.03M | -42.99M |
| Income Before Tax | -48.50M | -47.53M | -40.56M | -42.03M | -37.34M |
| Income Tax Expenses | -- | 117.00K | -- | -- | -- |
| Earnings from Continuing Operations | -48.50M | -47.65M | -40.56M | -42.03M | -37.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | -- | -- | 192.00K |
| Net Income | -48.50M | -47.65M | -40.56M | -42.03M | -37.15M |
| EBIT | -55.00M | -55.05M | -48.86M | -50.03M | -42.99M |
| EBITDA | -54.92M | -54.97M | -48.78M | -49.95M | -42.91M |
| EPS Basic | -0.82 | -0.81 | -0.70 | -0.76 | -0.86 |
| Normalized Basic EPS | -0.51 | -0.51 | -0.43 | -0.48 | -0.54 |
| EPS Diluted | -0.82 | -0.81 | -0.70 | -0.76 | -0.86 |
| Normalized Diluted EPS | -0.51 | -0.51 | -0.43 | -0.48 | -0.54 |
| Average Basic Shares Outstanding | 58.91M | 58.58M | 58.34M | 55.05M | 43.01M |
| Average Diluted Shares Outstanding | 58.91M | 58.58M | 58.34M | 55.05M | 43.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |